9/22/2021 8:02:52 AM
INOVIO Gets Regulatory Authorization To Conduct Phase 3 Trial Of COVID-19 DNA Vaccine Candidate, INO-4800, In Mexico
8/26/2021 8:01:55 AM
INOVIO Says Gets Authorization To Conduct Phase 3 Efficacy Trial Of COVID-19 DNA Vaccine Candidate, INO-4800
8/9/2021 4:06:59 PM
INOVIO Q2 Loss/share $0.39 Vs. Loss $0.83 Year Ago
8/9/2021 8:02:47 AM
INOVIO, Advaccine Receive Regulatory Allowance For Two Heterologous Prime-Boost Clinical Trials In China Using INO-4800
8/4/2021 8:02:09 AM
INOVIO Doses First Participant In Phase 2 Trial For DNA Vaccine Against Middle East Respiratory Syndrome
6/3/2021 8:04:26 AM
Geneos Therapeutics Reports Positive Preliminary Results Of Its Ongoing First-in-human Trial
5/17/2021 8:02:45 AM
INOVIO Announces Appointment Of Roger Dansey To Board
5/10/2021 4:42:08 PM
INOVIO Q1 Total Revenue $371K Vs $1.3 Mln Last Year
5/10/2021 4:07:12 PM
INOVIO Q1 Loss/Shr $0.27 Vs Loss $0.26 Last Year
4/23/2021 8:09:13 AM
INOVIO Plans For Predominantly Ex-U.S. Phase 3 Trial For COVID-19 Vaccine Candidate, INO-4800